Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efepoetin alfa versus darbepoetin alfa for anemia in dialysis-dependent chronic kidney disease
2023-503634-50-01Phase 3Authorised
- Sponsor
- Genexine
- Start
- Jul 2025
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 3, randomised, single-blind trial in anemia of renal disease comparing GX-E4 with Aranesp (2 arms). Primary endpoint: Mean change from baseline in hemoglobin averaged over Week 20 to Week 28 without rescue therapy. Planned start Jul 2025; status: authorised.
02
Drugs
efepoetin alfadarbepoetin alfa
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on 2023-503634-50-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503634-50-01.